Martin N. Gerding

2.5k total citations
25 papers, 1.5k citations indexed

About

Martin N. Gerding is a scholar working on Pathology and Forensic Medicine, Endocrinology, Diabetes and Metabolism and Ophthalmology. According to data from OpenAlex, Martin N. Gerding has authored 25 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pathology and Forensic Medicine, 14 papers in Endocrinology, Diabetes and Metabolism and 10 papers in Ophthalmology. Recurrent topics in Martin N. Gerding's work include Ophthalmology and Eye Disorders (15 papers), Pituitary Gland Disorders and Treatments (9 papers) and Glaucoma and retinal disorders (9 papers). Martin N. Gerding is often cited by papers focused on Ophthalmology and Eye Disorders (15 papers), Pituitary Gland Disorders and Treatments (9 papers) and Glaucoma and retinal disorders (9 papers). Martin N. Gerding collaborates with scholars based in Netherlands, United States and Belgium. Martin N. Gerding's co-authors include Wilmar M. Wiersinga, Mark F. Prummel, Caroline B. Terwee, Friedo W. Dekker, Onno Bakker, Leo Koornneef, Maarten P. Mourits, M. F. Prummel, Albert D. M. E. Osterhaus and Jan Groen and has published in prestigious journals such as The Journal of Clinical Endocrinology & Metabolism, The Journal of Infectious Diseases and Journal of Clinical Epidemiology.

In The Last Decade

Martin N. Gerding

25 papers receiving 1.5k citations

Peers

Countries citing papers authored by Martin N. Gerding

Since Specialization

Citations

This map shows the geographic impact of Martin N. Gerding's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Martin N. Gerding with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Martin N. Gerding more than expected).

Fields of papers citing papers by Martin N. Gerding

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Martin N. Gerding. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Martin N. Gerding. The network helps show where Martin N. Gerding may publish in the future.

Co-authorship network of co-authors of Martin N. Gerding

This figure shows the co-authorship network connecting the top 25 collaborators of Martin N. Gerding. A scholar is included among the top collaborators of Martin N. Gerding based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Martin N. Gerding. Martin N. Gerding is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Bihormonal fully closed-loop system for the treatment of type 1 diabetes: a real-world multicentre, prospective, single-arm trial in the Netherlands 2024 ·The Lancet Digital Health ·Arianne C. van Bon, (unknown), (unknown), Gozewijn D. Laverman, (unknown), (unknown), A. H. L. Mulder, Mattijs Out, R. Groote Veldman, (unknown), Bas Schouwenberg, Mechteld A. R. Vermeulen, (unknown), Martin N. Gerding, J.P.H. van Wijk, (unknown), Michelle Witkop, J. Hans DeVries	13
2	Natural helix 9 mutants of PPARγ differently affect its transcriptional activity 2018 ·Molecular Metabolism ·Marjoleine F. Broekema, Maarten P.G. Massink, Cinzia Donato, Joep de Ligt, Jörg Schaarschmidt, (unknown), Marieke G. Schooneman, Diana Melchers, Martin N. Gerding, René Houtman, Alexandre M. J. J. Bonvin, Amit R. Majithia, Houshang Monajemi, (unknown), Maarten R. Soeters, Eric Kalkhoven	14
3	Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population 2011 ·Journal of Diabetes ·Erik Badings, (unknown), (unknown), Dirk J. Lok, (unknown), Martin N. Gerding, Hertzel C. Gerstein, Jan G.P. Tijssen	5
4	Measuring disease activity to predict therapeutic outcome in Graves’ ophthalmopathy 2005 ·Clinical Endocrinology ·Caroline B. Terwee, Mark F. Prummel, Martin N. Gerding, George J. Kahaly, Friedo W. Dekker, Wilmar M. Wiersinga	58
5	Interpretation and validity of changes in scores on the Graves' ophthalmopathy quality of life questionnaire (GO‐QOL) after different treatments 2001 ·Clinical Endocrinology ·Caroline B. Terwee, Friedo W. Dekker, Maarten P. Mourits, Martin N. Gerding, L. Baldeschi, Rachel Kalmann, M. F. Prummel, Wilmar M. Wiersinga	150
6	The usefulness of quantitative orbital magnetic resonance imaging in Graves' ophthalmopathy 2001 ·Clinical Endocrinology ·(unknown), Martin N. Gerding, Frans W. Zonneveld, Wilmar M. Wiersinga	41
7	Assessment of disease activity in Graves' ophthalmopathy by orbital ultrasonography and clinical parameters 2000 ·Clinical Endocrinology ·Martin N. Gerding, Mark F. Prummel, Wilmar M. Wiersinga	47
8	Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy 2000 ·Clinical Endocrinology ·Martin N. Gerding, (unknown), (unknown), Onno Bakker, Wilmar M. Wiersinga, Mark F. Prummel	238
9	Octreotide‐scintigraphy is a disease‐activity parameter in Graves' ophthalmopathy 1999 ·Clinical Endocrinology ·Martin N. Gerding, Friso M. van der Zant, Eric A. van Royen, Leo Koornneef, E. P. Krenning, W. M. Wiersinga, Mark F. Prummel	55
10	Test-Retest Reliability of the GO-QOL 1999 ·Journal of Clinical Epidemiology ·Caroline B. Terwee, Martin N. Gerding, Friedo W. Dekker, M. F. Prummel, (unknown), Wilmar M. Wiersinga	81
11	Assessment of disease activity in Graves' ophthalmopathy 1999 ·UvA-DARE (University of Amsterdam) ·Martin N. Gerding	2
12	Development of a disease specific quality of life questionnaire for patients with Graves' ophthalmopathy: the GO-QOL 1998 ·British Journal of Ophthalmology ·Caroline B. Terwee, Martin N. Gerding, Friedo W. Dekker, Mark F. Prummel, Wilmar M. Wiersinga	217
13	Octreotide Scintigraphy in Thyroidal and Orbital Graves' Disease 1998 ·Thyroid ·Wilmar M. Wiersinga, Martin N. Gerding, Mark F. Prummel, E. P. Krenning	17
14	DEVELOPMENT OF A DISEASE SPECIFIC QUALITY OF LIFE QUESTIONNAIRE FOR PATIENTS WITH GRAVE’S OPHTHALMOPATHY: THE GO-QOL 1998 ·PubMed Central ·Caroline B. Terwee, Martin N. Gerding, Friedo W. Dekker, M. F. Prummel, (unknown)	3
15	The use of colour slides in the assessment of changes in soft-tissue involvement in Graves’ ophthalmopathy 1998 ·Journal of Endocrinological Investigation ·Martin N. Gerding, Mark F. Prummel, Rachel Kalmann, Leo Koornneef, Wilmar M. Wiersinga	16
16	Quality of Life in Patients with Graves' Ophthalmopathy is Markedly Decreased: Measurement by the Medical Outcomes Study Instrument 1997 ·Thyroid ·Martin N. Gerding, Caroline B. Terwee, Friedo W. Dekker, Leo Koornneef, Mark F. Prummel, Wilmar M. Wiersinga	164
17	A Macaque Model for Hantavirus Infection 1995 ·The Journal of Infectious Diseases ·Jan Groen, Martin N. Gerding, J.P. Koeman, Paul Roholl, Geert van Amerongen, (unknown), Hubert G.M. Niesters, Albert D. M. E. Osterhaus	58
18	Hantavirus nephropathy in the Netherlands: clinical, histopathological and epidemiological findings 1995 ·The Netherlands Journal of Medicine ·Martin N. Gerding	4
19	Hantavirus infections in The Netherlands: epidemiology and disease 1995 ·Epidemiology and Infection ·Jan Groen, Martin N. Gerding, J. G. M. Jordans, Jan Clément, (unknown), Albert D. M. E. Osterhaus	64
20	Class and subclass distribution of hantavirus‐specific serum antibodies at different times after the onset of nephropathia epidemica 1994 ·Journal of Medical Virology ·Jan Groen, Martin N. Gerding, J. G. M. Jordans, Jan Clément, Albert D. M. E. Osterhaus	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact